Can Lung Scar Tissue Turn Into Cancer?

Lung scar tissue does not simply “turn into” cancer the way a healthy cell mutates, but scarred and fibrotic lung tissue creates an environment where cancer is significantly more likely to develop. In people with idiopathic pulmonary fibrosis, roughly one in seven will be diagnosed with lung cancer within five years. For decades, doctors debated whether the scar came first or the tumor did, and the answer turned out to be more complicated than either camp expected.

The Rise and Fall of “Scar Carcinoma”

In 1939, a pathologist named Friedrich described what he called scar carcinoma: lung cancers that appeared to grow out of old peripheral scars. The idea stuck around for decades, treated as a recognized pathological entity. The logic seemed straightforward. Patients had old scars from tuberculosis, surgery, or prior infections, and cancers would show up in or near those scarred areas. It looked like the scar was the starting point.

By the 1980s, researchers started looking more carefully at the collagen inside these so-called scar carcinomas. What they found upended the original concept. The scars contained type III collagen and myofibroblasts, hallmarks of active, immature fibrosis, not the mature, stable type I and type V collagen you see in old healed scars. That meant the fibrous tissue was not a relic from some prior injury. It was being actively produced, likely as a reaction to the growing tumor itself.

Separate analysis of the extracellular matrix in these tumors reinforced the conclusion: what had been called scar carcinomas were most likely desmoplastic carcinomas, meaning the tumor itself was provoking the surrounding tissue to scar, not the other way around.

So the neat story of “scar becomes cancer” collapsed. But that did not mean scarring and cancer were unrelated. The relationship just turned out to be less direct and more interesting than a simple cause-and-effect chain.

How Fibrotic Lungs Become Cancer-Prone

Even though old scars do not transform directly into tumors, widespread lung fibrosis creates conditions that strongly favor cancer development. The connection runs through at least two major pathways: chronic inflammation and physical changes to the tissue itself.

When lung tissue is repeatedly injured and inflamed, as happens in conditions like tuberculosis or autoimmune lung disease, the immune system produces reactive oxygen species, prostaglandins, and cytokines at high levels. These chemicals damage DNA in surrounding cells. At the same time, inflammatory signaling ramps up production of proteins that prevent damaged cells from dying off the way they normally would. The combination of more DNA damage and less cellular cleanup creates fertile ground for cancerous mutations to accumulate.

The second pathway involves the physical stiffening of the tissue. In fibrotic lungs, collagen accumulates and becomes heavily cross-linked, making the tissue dramatically stiffer than normal. This stiffness is not just structural. It activates signaling pathways inside cells through mechanical sensors embedded in the cell surface. When cells feel a stiffer environment, they turn on growth and survival programs that would normally remain quiet. Research has identified a specific channel called Piezo1 that senses this mechanical tension. Its activation triggers a cascade that bypasses normal growth-control checkpoints, pushing cells toward a more aggressive and less regulated state.

⁴

In non-small cell lung cancer specifically, this stiffened matrix drives cells toward epithelial-mesenchymal transition, a process where cells become more mobile and invasive, and helps tumors evade the immune system. The same mechanical signals that make tissue feel rigid to the touch are actively helping cancer cells resist treatment and spread.

⁵

The Numbers Behind Fibrosis-Associated Lung Cancer

The strongest epidemiological evidence comes from studies of idiopathic pulmonary fibrosis, the most common form of progressive lung scarring with no known external cause. A systematic review pooling data from 35 studies and nearly 132,000 IPF patients found that about 14% developed lung cancer, a rate roughly six times higher than in the general population after adjusting for age, sex, and smoking.

⁶ A separate meta-analysis calculated an adjusted incidence rate ratio of about 6.4 compared to people without IPF, and found that roughly 10% of deaths in IPF patients were attributable to lung cancer.

⁷

The cancer risk was dramatically higher in men and in smokers, roughly nine times greater in each group compared to women and nonsmokers, respectively.

⁶

Even for people without a formal fibrosis diagnosis, the mere presence of scarring visible on a chest X-ray carries a measurable risk increase. A large screening trial found that people with any pulmonary scarring had about a 50% higher risk of developing lung cancer after adjusting for smoking and other factors. Bilateral or diffuse scarring carried a higher risk than a single small scar, and cancer was more likely to appear on the same side as the scarring, not the opposite lung.

⁸

Tuberculosis Scars and Cancer

Among all the causes of lung scarring, tuberculosis stands out. TB scars account for roughly three-quarters of cases where cancer develops in or near a scarred area, and previously cured TB is considered the second most common risk factor for lung cancer after smoking. About 3% of TB patients go on to develop lung cancer as a secondary condition.

⁹

Cancers arising near TB scars tend to be peripheral, meaning they grow in the outer portions of the lung rather than near the central airways. They are usually found in the upper lobes, where TB damage concentrates, and are predominantly adenocarcinomas, often small at the time of detection. These tumors are more common in men.

¹⁰

The inflammation mechanism described earlier is particularly relevant to TB. The body mounts a sustained immune assault against macrophages harboring the bacteria, producing large amounts of reactive oxygen species and inflammatory molecules over months or years. Even after the infection is cured, the residual fibrosis and chronic low-grade inflammation can persist indefinitely in the surrounding tissue.

Occupational and Environmental Scarring

Silicosis, caused by prolonged inhalation of crystalline silica dust in mining, construction, and similar industries, is another route from scarring to cancer. The inhaled particles trigger progressive fibrosis that, over years, raises the risk of lung cancer. This is not simply a matter of the particles themselves being carcinogenic. Epidemiological studies have shown that silica exposure increases cancer risk even after accounting for cigarette smoking, and animal models confirm that chronic silicosis independently promotes lung tumor development.

¹¹

Experimental work in rats has shown that silica exposure induces a granulomatous reaction with progressive fibrosis, followed by overgrowth of the cells lining the air sacs, and eventually frank carcinomas, essentially reproducing the full progression from scarring to cancer in a controlled setting.

¹²

Asbestos follows a broadly similar pattern: the fibers cause asbestosis (lung fibrosis), and the fibrotic tissue raises the likelihood of both lung cancer and mesothelioma. Workers with a history of heavy dust exposure in any industry where lung scarring is an occupational hazard carry elevated cancer risk for life, even decades after exposure ends.

Autoimmune Disease and Lung Fibrosis

Lung scarring is not always caused by infections or inhaled particles. Autoimmune conditions like rheumatoid arthritis can produce interstitial lung disease, a form of fibrosis driven by the body’s own immune system attacking lung tissue. When this happens, the cancer risk jumps considerably.

A study comparing rheumatoid arthritis patients with and without interstitial lung disease found that those who had developed lung fibrosis faced roughly three times the risk of lung cancer compared to people without RA. Patients with RA but no lung involvement had a more modest increase of about 1.6 times the risk.

¹³

When fibrosis and emphysema occur together in RA patients, which happens at a surprisingly high rate, outcomes worsen further. RA patients with combined pulmonary fibrosis and emphysema had a five-year death probability from lung cancer of about 71%, compared to 24% for patients without either lung condition. Both RA itself and the combined fibrosis-emphysema pattern were independent predictors of dying from lung cancer.

¹⁴

Why Detecting Cancer in Scarred Lungs Is Difficult

One of the most practical problems with fibrosis-associated lung cancer is that it is hard to spot early. On CT scans, fibrotic tissue already looks abnormal: it has honeycombing, thickened walls, ground-glass opacities, and irregular densities. A small tumor growing within that mess of scar tissue can easily be mistaken for another area of fibrosis, or dismissed as a stable abnormality.

Imaging studies have tried to identify CT features that distinguish scar-associated cancers from benign scarring. Certain signs like spiculation (spiky edges), vascular convergence (blood vessels being pulled toward a spot), and changes in ground-glass opacity over time can help differentiate the two, but the overlap is substantial. By the time a tumor is definitively identified, patients often have advanced disease. In one study of IPF patients who developed lung cancer, the majority already had stage IV disease at diagnosis.

¹⁵

Researchers are exploring blood-based biomarkers and genetic signatures to improve early detection. Candidate markers include tumor-associated proteins like CEA and CYFRA 21-1, along with circulating microRNAs, though none have been validated for routine clinical use yet. The hope is that combining these molecular signals with regular imaging could catch cancers earlier in high-risk fibrosis patients.

¹⁶

Treatment Gets Complicated

When lung cancer does develop in someone with pre-existing fibrosis, every standard treatment option carries additional risk. Surgery can trigger acute exacerbation of the underlying fibrosis, a sudden, life-threatening worsening of the lung disease. A meta-analysis found that about 15% of patients with usual interstitial pneumonia (the most common pattern of IPF) experienced an acute exacerbation after lung cancer resection. Smaller resections (removing less tissue) significantly reduced this risk without apparent harm to overall survival.

¹⁷

In one surgical series, the hospital mortality rate for IPF patients undergoing lung cancer surgery was about 7%, compared to roughly 2% for patients without fibrosis, with all four deaths in the IPF group caused by acute exacerbation of fibrosis rather than by the cancer surgery itself.

¹⁸

Immunotherapy presents its own dilemma. Immune checkpoint inhibitors have transformed lung cancer treatment, but they work by unleashing the immune system, which in fibrotic lungs can trigger severe pneumonitis (lung inflammation). One retrospective study found that about 35% of patients with pre-existing fibrosis developed pneumonitis on anti-PD-1 therapy, compared to around 6% of those without fibrosis.

¹⁹ However, a larger nationwide study found no significant difference in pneumonitis rates between patients with and without interstitial lung disease, suggesting the risk may depend on the severity and type of fibrosis rather than its mere presence.

²⁰ The conflicting evidence means treatment decisions for these patients often involve difficult case-by-case weighing of cancer risk against lung toxicity risk.

²¹

Antifibrotic Drugs and Cancer Protection

An intriguing development is the finding that antifibrotic medications, drugs originally designed to slow the progression of lung fibrosis, may also reduce cancer risk or improve outcomes when cancer does develop. Pirfenidone, one of the two approved antifibrotic drugs for IPF, was associated with significantly better survival in IPF patients who developed lung cancer compared to those not taking the drug.

²²

The benefits extend to the surgical setting as well. A meta-analysis of perioperative antifibrotic therapy in IPF patients undergoing lung cancer surgery found a 69% reduction in the risk of acute exacerbation and an 81% reduction in 90-day mortality. Patients on antifibrotic drugs also had shorter hospital stays and fewer complications like prolonged air leaks. Side effects were mild, mostly limited to nausea and sun sensitivity.

²³

Whether these drugs work by slowing the fibrotic process that promotes cancer, by reducing the stiffness-driven signaling that pushes cells toward malignancy, or by stabilizing the lungs enough to tolerate treatment is still being sorted out. But for IPF patients facing cancer surgery, the evidence for perioperative antifibrotic therapy is becoming hard to ignore.

What Type of Cancer Develops

The cancers that arise in fibrotic lungs are not a random sampling of all lung cancer types. Adenocarcinoma is by far the most common subtype, which makes sense given that the cells most affected by fibrosis are the epithelial cells lining the small airways and air sacs, exactly the cell type that gives rise to adenocarcinomas. However, at least one study found that the presence of scarring in the same lobe as a tumor was not reliably associated with any single histological subtype, meaning other types including squamous cell carcinoma and small cell lung cancer also occur in scarred lungs.

¹⁵

The cancers also tend to develop in a specific pattern. They are peripheral rather than central, meaning they grow in the outer lung tissue where fibrosis is usually worst, not near the large bronchi. They are more often found in the lower lobes in IPF (where the fibrosis concentrates) and in the upper lobes in TB-related scarring (where TB damage concentrates). This geographic correlation between where the scar tissue is heaviest and where the cancer appears is among the strongest circumstantial evidence that fibrosis actively contributes to cancer development rather than the two simply coexisting by coincidence.

Screening and Monitoring for People with Lung Scarring

There is no universally adopted screening protocol specifically for cancer in fibrotic lungs, which is a gap many pulmonologists find frustrating. Standard low-dose CT screening guidelines target people based on age and smoking history, and many fibrosis patients qualify on those grounds anyway. But the difficulty of distinguishing a new nodule from background fibrosis means that even regular CT scans can miss tumors or lead to unnecessary biopsies.

The finding that cancer tends to develop on the same side as the scarring, and that bilateral or diffuse scarring carries higher risk than a single discrete scar, has practical implications for how closely these patients should be watched.

⁸ If you have been told you have pulmonary fibrosis or scarring on an imaging study, asking your doctor about cancer surveillance is reasonable regardless of your smoking history. The elevated risk exists even in nonsmokers with fibrosis, though smoking multiplies it dramatically.

For people with a history of tuberculosis, particularly in countries where TB is common, the cancer risk associated with residual scarring is an underappreciated concern. A cured TB infection does not mean the story is over for your lungs. The scars left behind continue to create an environment where chronic inflammation and altered tissue mechanics raise the odds of cancer years or even decades later.

1
PubMed. Scar carcinoma of the lung: a historical perspective
2
PubMed Central. The extracellular matrix of pulmonary scar carcinomas is suggestive of a desmoplastic origin
3
PubMed. Inflammation as cause for scar cancers of the lung
4
PubMed Central. The mechano-immunological barrier in fibrosis-associated lung cancer: targeting matrix stiffness and the Piezo1 axis for microenvironment normalization
5
PubMed. Mechanobiology of non-small cell lung cancer: bridging tumor mechanics and therapeutic strategies
6
PLOS ONE. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
7
Annals of the American Thoracic Society. Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis
8
Archives of Internal Medicine. Lung Cancer Risk Following Detection of Pulmonary Scarring by Chest Radiography in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
9
PubMed Central. New progress of tuberculosis scar carcinoma
10
PubMed Central. Follow-up of an occult tuberculosis scar cancer after resection of metastatic lesions
11
PubMed Central. Silicosis and lung cancer: current perspectives
12
PubMed Central. Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer
13
PubMed Central. The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
14
PLOS ONE. Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study
15
PubMed Central. Pulmonary scarring and its relation to primary lung cancer
16
PubMed Central. A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer
17
BMJ. Lung cancer resection in patients with underlying usual interstitial pneumonia: a meta-analysis
18
The Journal of Thoracic and Cardiovascular Surgery. Surgical treatment for primary lung cancer concomitant with idiopathic pulmonary fibrosis
19
PubMed. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
20
PubMed Central. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study
21
PubMed Central. Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease
22
PubMed Central. Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis
23
PubMed. Perioperative antifibrotic therapy for patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery: A systematic review and meta-analysis